NAFLD and Chronic Kidney Disease

Morgan Marcuccilli, Michel Chonchol, Morgan Marcuccilli, Michel Chonchol

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries and it is now considered a risk factor for cardiovascular disease. Evidence linking NAFLD to the development and progression of chronic kidney disease (CKD) is emerging as a popular area of scientific interest. The rise in simultaneous liver-kidney transplantation as well as the significant cost associated with the presence of chronic kidney disease in the NAFLD population make this entity a worthwhile target for screening and therapeutic intervention. While several cross-sectional and case control studies have been published to substantiate these theories, very little data exists on the underlying cause of NAFLD and CKD. In this review, we will discuss the most recent publications on the diagnosis of NAFLD as well new evidence regarding the pathophysiology of NAFLD and CKD as an inflammatory disorder. These mechanisms include the role of obesity, the renin-angiotensin system, and dysregulation of fructose metabolism and lipogenesis in the development of both disorders. Further investigation of these pathways may lead to novel therapies that aim to target the NAFLD and CKD. However, more prospective studies that include information on both renal and liver histology will be necessary in order to understand the relationship between these diseases.

Keywords: chronic kidney disease; inflammation; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; review.

Figures

Figure 1
Figure 1
This figure demonstrates the various mechanisms associated with non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD). The liver-kidney crosstalk in NAFLD includes altered renin-angiotensin system (RAS) and activated protein kinase (AMPK) activation, impaired antioxidant defense, and excessive dietary fructose intake, which affects renal injury through altered lipogenesis and inflammatory response. In turn, 8 the kidney reacts promoting further RAS activation, increased angiotensin II (ANGII) and uric acid production in a vicious cycle leading to fibrosis [20].

References

    1. Vernon G., Baranova A., Younossi Z.M. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011;34:274–285. doi: 10.1111/j.1365-2036.2011.04724.x.
    1. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.
    1. Loomba R., Sanyal A.J. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013;10:686–690. doi: 10.1038/nrgastro.2013.171.
    1. McCullough K., Sharma P., Ali T., Khan I., Smith W.C., MacLeod A., Black C. Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol. Dial. Transplant. 2012;27:1812–1821. doi: 10.1093/ndt/gfr547.
    1. Targher G., Chonchol M.B., Byrne C.D. CKD and non-alcoholic fatty liver disease. AJKD. 2014;64:638–652. doi: 10.1053/j.ajkd.2014.05.019.
    1. Black C., Sharma P., Scotland G., McCullough K., McGurn D., Robertson L., Fluck N., MacLeod A., McNamee P., Prescott G., et al. Early referral strategies for management of people with markers of renal disease: A systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol. Assess. 2010;14:1–184. doi: 10.3310/hta14210.
    1. Athyros V., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., Mikhailidis D.P. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease; an update. World J. Gastroenterol. 2015;21:6820–6834.
    1. Singal A.K., Salameh H., Kuo Y.F., Wiesner R.H. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation. 2014;98:216–221. doi: 10.1097/TP.0000000000000048.
    1. Coresh J., Byrd-Holt D., Astor B.C., Briggs J.P., Eggers P.W., Lacher D.A., Hostetter T.H. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J. Am. Soc. Nephrol. 2005;16:180–188. doi: 10.1681/ASN.2004070539.
    1. Kim D., Kim W.R., Kim H.J., Therneau T.M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–1365. doi: 10.1002/hep.26156.
    1. Hernaez R., Lazo M., Bonekamp S., Kamel I., Brancati F.L., Guallar E., Clark J.M. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54:1082–1090. doi: 10.1002/hep.24452.
    1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013;10:330–344. doi: 10.1038/nrgastro.2013.41.
    1. Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review; the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011;33:525–540. doi: 10.1111/j.1365-2036.2010.04556.x.
    1. Mikolasevic I., Racki S., Bubic I., Jelic I., Stimac D., Orlic L. Chronic kidney disease and nonalcoholic fatty liver disease proven by transient elastography. Kidney Blood Press Res. 2013;37:305–310. doi: 10.1159/000350158.
    1. Mikolasevic I., Orlic L., Zaputovic L., Racki S., Cubranic Z., Anic K., Devcic B., Stimac D. Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wien. Klin. Wochenschr. 2015;127:451–458. doi: 10.1007/s00508-015-0757-z.
    1. Satapathy S.K., Garg S., Chauhan R., Sakhuja P., Malhotra V., Sharma B.C., Sarin S.K. Beneficial effects of tumor necrosis factor-α inhibition by pentoxyfilline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004;99:1946–1952. doi: 10.1111/j.1572-0241.2004.40220.x.
    1. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., Hubscher S., Roskams T., Pinzani M., Arthur M.J. European Liver Fibrosis Group: Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology. 2004;127:1704–1713. doi: 10.1053/j.gastro.2004.08.052.
    1. Ratziu V., Gira P., Charlotte F., Bruckert E., Thibault V., Theodorou I., Khalil L., Turpin G., Opolon P., Poynard T. Liver fibrosis in overweight patient. Gastroenterology. 2000;118:1117–1123. doi: 10.1016/S0016-5085(00)70364-7.
    1. Ratziu V., Massard J., Charlotte F., Messous D., Imbert-Bismut F., Bonyhay L., Tahiri M., Munteanu M., Thabut D., Cadranel J.F., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. doi: 10.1186/1471-230X-6-6.
    1. Angulo P., Keach J.C., Batts K.P., Lindor K.D. Independent predictor of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362. doi: 10.1002/hep.510300604.
    1. Harrison S.A., Oliver D., Arnod H.L., Gogia S., Neuschwander-Tetri B.A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–1447. doi: 10.1136/gut.2007.146019.
    1. Cales P., Laine F., Boursier J., Deugnier Y., Moal V., Oberti F., Hunault G., Rousselet M.C., Hubert I., Laafi J., et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J. Hepatol. 2009;50:165–173. doi: 10.1016/j.jhep.2008.07.035.
    1. Shah A., Lydecker A., Murray K., Tetri B.N., Contos M.J., Sanyal A.J. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009;7:1104–1112. doi: 10.1016/j.cgh.2009.05.033.
    1. Sumida Y., Yoneda M., Hyogo H., Yamaguchi K., Ono M., Fujii H., Eguchi Y., Suzuki Y., Imai S., Kanemasa K., et al. Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD): A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J. Gastroenterol. 2011;46:257–268. doi: 10.1007/s00535-010-0305-6.
    1. Younossi Z., Page S., Rafiq N., Birerdinc A., Stepanova M., Hossain N., Afendy A., Younoszai Z., Goodman Z., Baranova A. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes. Surg. 2011;21:431–439. doi: 10.1007/s11695-010-0204-1.
    1. Pearce S.G., Thosani N.C., Pan J. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark. Res. 2013;1:7. doi: 10.1186/2050-7771-1-7.
    1. Xu H.W., Hsu Y.C., Chang C.H., Wei K.L., Lin C.L. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol. Int. 2016;10:340–346. doi: 10.1007/s12072-015-9690-5.
    1. Musso G., Gambino R., Tabibian J.H., Ekstedt M., Kechagias S., Hamaguchi M., Hultcrantz R., Hagström H., Yoon S.K., Charatcharoenwitthaya P., et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLoS Med. 2014;11:562. doi: 10.1371/journal.pmed.1001680.
    1. Targher G., Bertolini L., Rodella S., Zoppini G., Lippi G., Day C., Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444–450. doi: 10.1007/s00125-007-0897-4.
    1. Campos G.M., Bambha K., Vittinghoff E., Rabl C., Posselt A.M., Ciovica R., Tiwari U., Ferrel L., Pabst M., Bass N.M., et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916–1923. doi: 10.1002/hep.22241.
    1. Chang Y., Ryu S., Sung E., Woo H.Y., Oh E., Cha K., Jung E., Kim W.S. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57:569–576. doi: 10.1016/j.metabol.2007.11.022.
    1. Targher G., Chonchol M., Bertolini L., Rodella S., Zenari L., Ciovica R., Tiwari U., Ferrel L., Pabst M., Bass N.M., et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J. Am. Soc. Nephrol. 2008;19:1564–1570. doi: 10.1681/ASN.2007101155.
    1. Targher G., Bertolini L., Chonchol M., Rodella S., Zoppini G., Lippi G. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341–1348. doi: 10.1007/s00125-010-1720-1.
    1. Targher G., Bertolini L., Rodella S., Lippi G., Zoppini G., Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin. J. Am. Soc. Nephrol. 2010;5:2166–2171. doi: 10.2215/CJN.05050610.
    1. Yilmaz Y., Alahdab Y.O., Yonal O., Kurt R., Kedrah A.E., Celikel C.A., Ozdogan O., Duman D., Imeryuz N., Avsar E., et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Metabolism. 2010;59:1327–1330. doi: 10.1016/j.metabol.2009.12.012.
    1. Söderberg C., Stål P., Askling J., Glaumann H., Lindberg G., Marmur J., Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602. doi: 10.1002/hep.23314.
    1. Wong V.W., Wong G.L., Choi P.C., Chan A.W., Li M.K., Chan H.Y., Chim A.M., Yu J., Sung J.J., Chan H.L. Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974. doi: 10.1136/gut.2009.205088.
    1. Lau K., Lorbeer R., Haring R., Schmidt C.O., Wallaschofski H., Nauck M., John U., Baumeister S.E., Völzke H. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J. Hypertens. 2010;28:1829–1835. doi: 10.1097/HJH.0b013e32833c211b.
    1. Yasui K., Sumida Y., Mori Y., Mitsuyoshi H., Minami M., Itoh Y., Kanemasa K., Matsubara H., Okanoue T., Yoshikawa T. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism. 2011;60:735–739. doi: 10.1016/j.metabol.2010.07.022.
    1. Machado M.V., Gonçalves S., Carepa F., Coutinho J., Costa A., Cortez-Pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int. 2012;32:241–248. doi: 10.1111/j.1478-3231.2011.02623.x.
    1. Targher G., Pichiri I., Zoppini G., Trombetta M., Bonora E. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet. Med. 2012;29:220–226. doi: 10.1111/j.1464-5491.2011.03427.x.
    1. Sirota J.C., McFann K., Targher G., Chonchol M., Jalal D.I. Association between nonalcoholic liver disease and chronic kidney disease: An ultrasound analysis from NHANES 1988–1994. Am. J. Nephrol. 2012;36:466–471. doi: 10.1159/000343885.
    1. Armstrong M.J., Houlihan D.D., Bentham L., Shaw J.C., Cramb R., Olliff S., Gill P.S., Neuberger J.M., Lilford R.J., Newsome P.N. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol. 2012;56:234–240. doi: 10.1016/j.jhep.2011.03.020.
    1. Musso G., Cassader M., de Michieli F., Rosina F., Orlandi F., Gambino R. Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein. Metab. Hepatol. 2012;56:933–942. doi: 10.1002/hep.25739.
    1. Francque S.M., Verrijken A., Mertens I., Hubens G., van Marck E., Pelckmans P., Michielsen P., van Gaal L. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin. Gastroenterol. Hepatol. 2012;10:1162–1168. doi: 10.1016/j.cgh.2012.06.019.
    1. Casoinic F., Sâmpelean D., Bădău C., Prună L. Nonalcoholic fatty liver disease–A risk factor for microalbuminuria in type 2 diabetic patients. Rom. J. Int. Med. 2009;47:55–59.
    1. Xia M.F., Lin H.D., Li X.M., Yan H.M., Bian H., Chang X.X., He W.Y., Jeekel J., Hofman A., Gao X. Renal function-dependent association of serum uric acid with metabolic syndrome and hepatic fat content in a middle-aged and elderly Chinese population. Clin. Exp. Pharmacol. Physiol. 2012;39:930–937. doi: 10.1111/1440-1681.12011.
    1. Kim Y.S., Jung E.S., Hur W., Bae S.H., Choi J.Y., Chang X.X., He W.Y., Jeekel J., Hofman A., Gao X. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2013;19:120–130. doi: 10.3350/cmh.2013.19.2.120.
    1. Angulo P., Bugianesi E., Bjornsson E.S., Charatcharoenwitthaya P., Mills P.R., Barrera F., Haflidadottir S., Day C.P., George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782–789. doi: 10.1053/j.gastro.2013.06.057.
    1. El Azeem H.A., Khalek E.A., El-Akabawy H., Naeim H., Khalik H.A., Alfifi A.A. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J. Saudi. Heart Assoc. 2013;25:239–246. doi: 10.1016/j.jsha.2013.07.004.
    1. Musso G., Cassader M., Cohney S., Pinach S., Saba F., Gambino R. Emerging liver–kidney interactions in nonalcoholic fatty liver disease. Trends Mol. Med. 2015;21:645–662. doi: 10.1016/j.molmed.2015.08.005.
    1. Ogden C.L., Carroll M.D., Kit B.K., Flegal K.M. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814. doi: 10.1001/jama.2014.732.
    1. Ix J.H., Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK. J. Am. Soc. Nephrol. 2010;21:406–412. doi: 10.1681/ASN.2009080820.
    1. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., Omatsu T., Nakajima T., Sarui H., Shimazaki M., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005;143:722–728. doi: 10.7326/0003-4819-143-10-200511150-00009.
    1. Mathews S.T., Rakhade S., Zhou X., Parker G.C., Coscina D.V., Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem. Biophys. Res. Commun. 2006;350:437–443. doi: 10.1016/j.bbrc.2006.09.071.
    1. Ix J.H., Chertow G.M., Shlipak M.G., Brandenburg V.M., Ketteler M., Whooley M.A. Fetuin-A and kidney function in persons with coronary artery disease—Data from the Heart and Soul Study. Nephrol. Dial. Transplant. 2006;21:2144–2151. doi: 10.1093/ndt/gfl204.
    1. De Vries A.P., Ruggenenti P., Ruan X.Z., Praga M., Cruzado J.M., Bajema I.M., D'Agati V.D., Lamb H.J., Pongrac Barlovic D., Hojs R., et al. Fatty kidney: Emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2:417–426. doi: 10.1016/S2213-8587(14)70065-8.
    1. Osterreicher C.H., Taura K., de Minicis S., Seki E., Penz-Osterreicher M., Kodama Y., Kluwe J., Schuster M., Oudit G.Y., Penninger J.M., et al. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology. 2009;50:929–938. doi: 10.1002/hep.23104.
    1. Vos M., Kimmons J., Gillespie C., Welsh J., Blanck H. Dietary fructose consumption among US children and adults: The Third National Health and Nutrition Examination Survey. Medscape J. Med. 2008;10:160.
    1. Osterreicher C.H., Taura K., de Minicis S., Seki E., Penz-Osterreicher M., Kodama Y., Kluwe J., Schuster M., Oudit G.Y., Penninger J.M., et al. Betaine supplementation protects against high-fructose-induced renal injury in rats. J. Nutr. Biochem. 2014;25:353–362.
    1. Abdelmalek M.F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R.J., Diehl A.M. Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971. doi: 10.1002/hep.23535.
    1. Cheungpasitporn W., Thongprayoon C., O'Corragain O.A., Edmonds P.J., Kittanamongkolchai W., Erickson S.B. Associations of sugar and artificially sweetened soda and chronic kidney disease: A systematic review and meta-analysis. Nephrology. 2014;19:791–797. doi: 10.1111/nep.12343.
    1. Wang C., Cui Y., Li C., Zhang Y., Xu S., Li X., Li H., Zhang X. Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis. 2013;12:165–171. doi: 10.1186/1476-511X-12-165.
    1. Pergola P.E., Raskin P., Toto R.D., Meyer C.J., Huff W., Grossman E.B., Krauth M.A.B., Ruiz S., Audhya P., Christ-Schmidt H., et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 2011;365:327–336. doi: 10.1056/NEJMoa1105351.
    1. De Zeeuw D., Akizawa T., Agarwal R., Audhya P., Bakris G.L., Chin M., Krauth M., Lambers Heerspink H.J., Meyer C.J., McMurray J.J., et al. Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON) Am. J. Nephrol. 2013;37:212–222. doi: 10.1159/000346948.
    1. Hirata T., Tomita K., Kawai T., Yokoyama H., Shimada A., Kikuchi M., Hirose H., Ebinuma H., Irie J., Ojiro K., et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY) Int. J. Endocrinol. 2013;2013:587140. doi: 10.1155/2013/587140.
    1. Bain R., Rohde R., Hunsicker L.G., McGill J., Kobrin S., Lewis E.J. A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: Study design and patient characteristics. The Collaborative Study Group. J. Am. Soc. Nephrol. 1992;3:S97–S103.
    1. Orlic L., Mikolasevic I., Lukenda V., Anic K., Jelic I., Racki S. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien. Klin. Wochenschr. 2015;127:355–362. doi: 10.1007/s00508-014-0661-y.
    1. Singh S., Khera R., Allen A.M., Murad H., Loomba R. Comparative effectiveness of pharmacologic interventions for non-alcoholic steatohepatitis: A systemic review and network meta-analysis. Hepatology. 2015;62:1417–1432. doi: 10.1002/hep.27999.
    1. Athyros V.G., Tziomalos K., Gossios T.D., Griva T., Anagnostis P., Kargiotis K., Pagourelias E.D., Theocharidou E., Karagiannis A., Mikhailidis D.P. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet. 2010;376:1916–1922. doi: 10.1016/S0140-6736(10)61272-X.
    1. Tikkanen M.J., Fayyad R., Faergeman O., Olsson A.G., Wun C.C., Laskey R., Kastelein J.J., Holme I., Pedersen T.R. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int. J. Cardiol. 2013;168:3846–3852. doi: 10.1016/j.ijcard.2013.06.024.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner